ClinicalTrials.gg
Active, not recruitingNCT04152512PROVEUpdated Nov 1, 2023

Quality of Life, Unmet Needs and Satisfaction With Care After Vulvar Cancer

An observational study in Vulvar Cancer and Quality of Life, sponsored by Karolinska University Hospital. Active, not recruiting at 4 sites in Sweden. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-11-01.

Sponsored by Karolinska University Hospital · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
153
Ages
18 Years and older
Sex
Female
01

Study summary

The aim of this prospective, longitudinal Swedish multi-center study is to assess the quality of life, treatment-related morbidity, unmet needs and satisfaction with care after treatment for vulvar cancer, evaluated by a validated questionnaire.

Read the detailed description

PRIMARY OBJECTIVES:

Information about:

  • General and vulvar-cancer-specific quality of life before and after any treatment for newly diagnosed vulvar cancer
  • Treatment-related morbidity after any treatment for newly diagnosed vulvar cancer
  • Unmet needs of patients with newly diagnosed vulvar cancer
  • Satisfaction with care after any treatment for newly diagnosed vulvar cancer in Sweden.

OUTLINE:

The study is planned as a prospective, longitudinal multi-centre study in Sweden. Since 2017, the treatment of vulvar cancer patients has been accredited to four tertiary referral university hospitals in Sweden; the Sahlgrenska University hospital in Gothenburg, the Linköping University hospital, the Skåne University hospital in Lund and the Karolinska University hospital in Stockholm.

150 patients are estimated for inclusion during a time frame of about 18 months.

Eligible patients will be asked to complete a validated questionnaire at different points of time (before and after treatment). Calculating a response rate of about 50% - 60%, this will result in at least 80 completed questionnaires.

The questionnaires consist of the following parts:

  • European Organisation for Research and Treatment of Cancer (EORTC)-QLQ-C30
  • European Organisation for Research and Treatment of Cancer (EORTC)-QLQ-VU-34 (Vulva-specific module)
  • Hospital Depression and Anxiety Scale (HADS)
  • Supportive Care Needs Survey Short Form, excerpt (SCNS-SF34)
  • European Organisation for Research and Treatment of Cancer (EORTC)-PATSAT (Patient Satisfaction), excerpt
  • Demographic data
  • 25 self-constructed (and validated) questions

RESULTS:

Results are expected to be available in 2021.

02

Conditions studied

  • Vulvar Cancer
  • Quality of Life

Keywords

  • Questionnaire
  • EORTC QLQ C30 + VU34
  • Hospital Depression and Anxiety Scale
  • EORTC-PATSAT
  • Supportive Care Needs Survey Short Form
03

In context

Vulvar Neoplasms

236 studies on the registry are indexed under Vulvar Neoplasms; 69 are open to participants now.

This study's enrollment of 153 is close to the median of 152 across 58 observational studies indexed under Vulvar Neoplasms.

Browse Vulvar Neoplasms studies →

Lead sponsor

Karolinska University Hospital is the lead sponsor of 279 studies on the registry; 55 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Women with newly diagnosed invasive vulvar cancer in Sweden during the study time frame.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Primary diagnosis of vulvar cancer, all stages, all planned treatments

Exclusion criteria

Exclusion Criteria:

  • Disability to understand and complete the questionnaire due to language difficulties, severe psychiatric illness or dementia
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
153 participants (actual)
Patient registry
No

Groups and cohorts

  • Whole Cohort

    Whole cohort administration of questionnaire at 7 times

    Behavioral: Questionnaire administration

Interventions

  • BehavioralQuestionnaire administration

    Questionnaire administration (4 different forms: pre-treatment, 3-4 months after treatment, 1 year after treatment, 2-5 years (yearly) after treatment

06

What researchers measure

Primary outcomes

  1. Global quality of life

    Measured by the European Organisation of Research and Treatment of Cancer (EORTC)-QLQ-C30-questionnaire. Measurement on a scale between 0-and 100. Higher values represent better quality of life. A change of at least 5-8 points is regarded as clinically significant.

    Time frame: 1 year after end of treatment

  2. Vulvar-cancer-specific quality of life

    Measured by the EORTC-QLQ-VU34-questionnaire. Higher values represent higher quality of life.

    Time frame: 1 year after end of treatment

Secondary outcomes

  1. Satisfaction with Care

    Measured by EORTC-PATSAT-questionnaire. Higher score represent higher satisfaction with care.

    Time frame: 3--4 months after end of treatment

  2. Depression and anxiety

    Measured by the Hospital Anxiety and Depression Index (HADS)-questionnaire. Higher scores represent more depression and anxiety

    Time frame: 1 year after end of treatment.

  3. Unmet needs

    Measured by the Supportive Care Needs Survey-Short Form (SCNS-SF)-34-questionnaire. Higher scores represent higher needs.

    Time frame: 3-4 months after end of treatment.

07

Study locations

4 sites
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2019 (actual). Primary completion is estimated for Feb 2027, 90 months after the start.

Of 32 observational studies under Vulvar Neoplasms, half reached primary completion within 75 months of starting (the median), counting those still running; a quarter within 41. This study's planned 90 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 27, 2019
First posted
Nov 5, 2019
StartActual
Aug 29, 2019
Primary completionEst.
Feb 2027
CompletionEst.
Oct 2027
Last update
Nov 1, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 1, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04152512
Collaborators
University Hospital, Linkoeping, Skane University Hospital, Sahlgrenska University Hospital
Responsible party
Diana Zach (MD, senior consultant, Karolinska University Hospital) — Principal investigator
First posted
Nov 5, 2019
Start date
Aug 29, 2019
Primary completion
Feb 2027 (estimated)
Completion
Oct 2027 (estimated)
Last update
Nov 1, 2023

Study contacts

Diana Zach, MD
principal investigator · Karolinska University Hospital, Karolinska Institute, Stockholm, Sweden

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion